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INTRODUCTION 
Colorectal cancer is a frequent and lethal disease globally representing the third most commonly 
diagnosed cancer in males and the second in females
1
. Multidisciplinary management of metastatic 
patients has been demonstrated to prolong overall survival; thus, while there is a general consensus 
to administer aggressive regimens when tumor reduction could lead an unresectable metastasis to a 
possible resection, there is not unanimity on the management of patients with advanced disease not 
suitable for surgery. In fact, in this setting of patients, anti-cancer drugs may be administered singly 
or may be delayed in a “continuum of care” in patients with a slow-growing tumor to maximize 
outcome. In this sense, an easy available, low-cost predictive and prognostic tool could be useful to 
rationalize clinical resources. 
 
CEA is a complex glycoprotein produced by 90% of colorectal cancers. It can be measured in serum 
quantitatively, and its level in plasma can be useful as a marker of disease
2
. CEA has been 
extensively studied in metastatic colorectal cancer patients since the ‘70s and a considerable amount 
of literature has been published. In summary, CEA has been demonstrated to predict response to 
chemotherapy and overall survival
3,4,5
. All these studies, however, have a series of limitations: they 
enrolled a relatively low number of patients; the results of those studies reporting data from clinical 
trials comparing different chemotherapies can be hardly referred to the daily oncological routine as 
marker evaluation is a secondary aim and enrolled patients are selected by strict including and 
excluding criteria; patients with CEA levels below the upper normality threshold have never been 
studied as marker levels were considered as false negative. Finally, clinical response to 
chemotherapy is determined by the radiological workout normally performed at 3 and at 6 months 
after chemotherapy onset. Some authors described a solid correlation between marker variations 
and radiological tumor response
6
; considering that responding patients are those with a better 
prognosis, it is questionable whether a marker which simply reflects tumor burden could add 
something to the clinical management of these patients. 
Carbohydrate antigen 19-9 (CA 19-9) is a Lewis blood group oligosaccharide that is generated by 
exocrine epithelial cells. It has been extensively studied in pancreatic cancer patients and in those 
suffering from gastrointestinal neoplasm. In colorectal cancer patients its role has been questioned 
as it presents a lower sensitivity than CEA
7
.  
 
We then explored and compared the predictive and prognostic role of baseline CEA and CA 19-9 
levels and their variation during first-line chemotherapy in a large database of patients with 
advanced colorectal disease observed from the time of first metastasis appearance. In particular we 
described whether CEA and CA 19-9 levels simply parallel tumor burden variations or were 
independent marker of prognosis, helping oncologist to discriminate within responding patients 
those destined to have a worse prognosis, and within progressing patients those with a more 
favorable disease. 
 
PATIENTS AND METHODS 
 
Patients and study design 
Clinical databases of two Italian Institutes (University of Torino, Oncology Unit, San Luigi 
Gonzaga Hospital [center 1]; and University of Eastern Piedmont, Maggiore della Carità Hospital, 
Novara [center 2]) were investigated. Records related to those patients with metastatic colorectal 
cancer disease treated from 1998 up to the end of 2011 were extracted and constitute the basis of 
this study. Patients characteristics and characteristics of the primary tumor, disease free-interval,
 
site 
of recurrence, type of chemotherapy, response to therapy, progression free-survival (PFS) and 
overall survival (OS) together with CEA and CA 19-9 determinations before, after 3 and 6 months 
of first-line chemotherapy were put into a database generated for the purpose of this study. We 
analyzed the predictive and prognostic role of CEA and CA 19-9 and their variations during first-
line therapy in patients in whom basal and at least one measurement at 3 or at 6 months was present 
in the database. Finally, multivariate analysis in which CEA and CA 19-9 were considered as time-
dependent covariates was performed including only patients with marker values available for the 
three time points (see CONSORT Diagram). 
 
CEA and Ca 19-9 measurement.  
For each patient, CEA and Ca 19-9 were measured locally by mean of an automatic 
chemiluminescent microparticle immunoassay (CMIA). The upper limits of the reference range for 
CEA and CA 19-9 were defined—according to the manufacturer's instructions— with 5 ng/ml and 
37 U/mL, respectively.  
Four subgroups of patients for each marker were identified: group 0 (G0) including patients with 
marker levels always beneath the upper limit of normality for the entire observation period; group 1 
(G1) including patients with >50% reduction of marker levels or marker positive that became 
negative during chemotherapy; group 2 (G2) patients with no significant variations of marker 
values; group 3 (G3) patients with >50% increase of marker levels or marker negative that became 
positive during chemotherapy. Patients with marker decrease >50% at 3 months that increased 
>50% or remained stable at 6 months were included in G1; patients with marker increase >50% at 3 
months that decreased >50% from baseline at 6 months were included in G1; finally, patients with 
marker increase >50% at 3 months that remained stable at 6 months were included in G3. 
 
Outcome evaluation 
Response evaluation was performed under the standard assessment criteria used at each institution 
for the considered timeframe. Up to 2001, treatment response was classified according to 
International Union Against Cancer (UICC) criteria
8
, wherein complete response was defined as the 
complete disappearance of all detectable malignant disease, partial response as a decrease >50% in 
the sum of the products of the two longest perpendicular diameters of all measurable lesions, and 
progressive disease as an increase of at least 25% in the size of measurable lesions and the 
development of new lesions. After 2001, centers were invited to classify responses according to the 
RECIST criteria
9
, wherein response was defined as a decrease >30% in the sum of the longest 
diameters of target lesions, and a progressive disease as an increase >20% of this sum. Only the best 
tumor response was recorded. The two methods have been demonstrated to be comparable as 
agreement between the unidimensional and bidimensional criteria was generally found to be good 
and acceptable
9
. 
PFS and OS were estimated from first-line treatment onset till progression or death from any cause 
or date of the last follow-up. The cut-off date for the collection of data was December 31
st
, 2011. 
Patients not progressing or alive or lost to follow-up at the time of the cut-off date were censored at 
the time of the last follow-up examination. 
 
Statistical analyses 
The predefined end point of this study was to show a correlation of baseline CEA and CA 19-9, and 
their kinetics during first-line therapy with clinical response, PFS and OS. The predictive role of 
baseline marker values and their variations during therapy to identify patients responding to first-
line chemotherapy was explored using the chi-square test with Yates correction, when necessary. 
Differences between groups of non parametric unpaired variables were validated by the Mann-
Whitney U test when comparing two groups or the Kruskal-Wallis Analysis of Variance when 
analyzing multiple groups. Correlations between marker values (baseline and their variations) and 
PFS or OS were represented by survival curves plotted according to the Kaplan-Meier method and 
validated using the log-rank test. Multivariate survival analysis was performed according to the Cox 
proportional-hazards model with backward elimination. CEA, CA 19-9 and age were considered as 
continuous variable. Categorical variables were managed as follows: values of dichotomous 
variables were 1 and 0. When a cut-off limit was applied, 1 represented those values above the 
limit. As far as gender is concerned, male was coded as 1 and female as 0. Ordinal variables, such 
as stage of the primitive or Performance Status, were ranked according to their prognostic role with 
lower value assigned to the best option (i.e. stage A=1, stage D=4). The effect of the serially 
measured CEA and CA 19-9 values (CEA and CA 19-9 kinetics) was also modeled by using the 
Cox model where the logarithmic transformation of CEA and CA 19-9 values were treated as a 
time-varying covariate with a constant value between two measurements, according to the method 
proposed by Boek et al
10
. For the multivariate analysis of CEA and CA 19-9 kinetics, the three 
marker determinations during chemotherapy had to be available. All statistical computations were 
performed using SPSS for Windows Ver 16.0 and STATISTICA for Windows Ver. 6.0 software. 
 
 
RESULTS 
We extracted data regarding 937 patients with metastatic colorectal cancer, of whom 892, 644 from 
Center 1 and 248 from Center 2, met the eligibility criteria and entered the study (See CONSORT 
Diagram). Their characteristics are depicted on Table 1.  
 
CEA and CA 19-9 measurements 
Data on CEA were recorded in 888 patients at baseline, in 790 at 3 months, and in 755 at 6 months. 
The corresponding figures for CA 19-9 were: 883, 786, and 748, respectively. Median marker 
values (range) at baseline, after 3 months, and after 6 months of front-line therapy were: 15.6 ng/ml 
(0.1-32,380), 8.5 ng/ml (0.4-50,000), 8 ng/ml (0.1-68,076) for CEA; and 29 U/ml (0.1-56,000), 19.9 
U/ml (0.1-42,817), 20 U/ml (0.1-63,630) for CA 19-9, respectively (Table 1). At baseline, 602/888 
patients presented with CEA values greater than 5 ng/ml, whereas we recorded in the same patient 
setting circulating levels of CA 19-9 above 37 U/ml in 405/883 subjects. Thus, marker sensitivities 
resulted to be 67.8% and 45.9%, respectively. Forty-five patients were CEA negative and CA 19-9 
positive, with a combined sensitivity of 73.6% (647 positive patients out of 879 patients in whom 
the two markers were both determined). 
Basal and at least one CEA and CA 19-9 determination at 3 or 6 months were available for 824 and 
816 patients, respectively. According to study design, patients were grouped as summarized on 
Table 2. Median marker variations (lower - upper quartile) at 3 and 6 months were: -22.8% (-70.4% 
- 48.9%) and 0% (-70.4% - 100.0%) for CEA and -7.4% (-65.9% - 32.6%) and 0% (-62.6% - 
93.3%) for CA 19-9, respectively.  
 
Markers and tumor response to chemotherapy 
Data on tumor response after first-line chemotherapy were available in 840 patients. Clinical 
response was evident in 312 patients (37.2%), whereas 318 (37.8%) obtained a stabilization of the 
disease and 210 (25.0%) progressed. Figure 1 summarizes marker variations according to clinical 
response. A good concordance between marker reduction (G1) and response to chemotherapy was 
more evident for CEA (50.2%) than for CA 19-9 (34.4%). The corresponding figures between G3 
and marker increase were 46,4% and 35,3% for CEA and CA 19-9, respectively. On the other hand, 
9,8% and 5,3% of those patients who obtained a clinical response had an increase in CEA and CA 
19-9 levels (G3), whereas in 14,6% and 9,4% of those who progressed to chemotherapy we 
recorded a decrease of CEA and CA 19-9 levels (G3), respectively. If we considered the 45 patients 
with normal CEA and abnormal CA 19-9 values at baseline, in 12 out of 16 (75%) who responded 
to therapy a marker decrease was recorded, whereas we found the opposite concordance in 6/10 
patients (60%) who progressed. Finally, CEA or CA 19-9 levels remained beneath the upper 
normality limit in a not negligible proportion of patients, with a higher proportion in those patients 
who obtained a disease response (26,9% for CEA and 52% for CA 19-9) than in those who 
progressed (13% and 32,1%, respectively. p<0.0001 for both markers). 
 
Markers and survivals 
At the time of data computation 730 (81.8%) patients had progressed. Median follow-up time 
(range) for those not progressing was 9 (0.7-173) months. A longer median PFS was recorded in 
those patients who presented normal CEA levels at baseline (15.1 vs 10.5 months; p<0.0001). A 
similar pattern was evident for those patients with CA 19-9 levels below the normality threshold at 
baseline (13.6 vs 10.2 months; p<0.0001). Median progression free-survivals for G0, G1, G2, and 
G3 were: 16.1, 12.1, 9.2, and 7.1 months for CEA (p<0.0001); 13.8, 11.9, 8.7, and 5.4 months for 
Ca 19-9 (p<0.0001), respectively. In the 45 patients with low CEA and high CA 19-9 at baseline, 
median PFS was 11.4 months. 
At 31
st
 December 2011, 610 patients (68.4%) had died. Median follow-up time (range) for the 
survivors was 19.6 (0.7-200.4) months. Survival curves are plotted on Figure 2. Patients with CEA 
levels beneath the normality limit at baseline survived longer than those with abnormal levels (32 vs 
22.3 months; p<0.0001). A similar figure was evident when analyzing those patients with normal vs 
those with abnormal CA 19-9 levels at baseline (30.5 vs 20.1 months; p<0.0001). 
Survival curves for each group are plotted on Figure 3 (CEA) and 4 (CA 19-9). Median survival 
times for G0, G1, G2, and G3 were: 36.3, 25.5, 17.8, and 17.0 months for CEA (p<0.0001); 31.7, 
23.9, 18.6, and 13.8 months for CA 19-9 (p<0.0001), respectively. In the 45 patients with low CEA 
and high CA 19-9 at baseline, median OS was 23.2 months. 
 
Multivariate analyses 
Multivariate Cox analyses on the impact on TTP and OS of baseline CEA and CA 19-9 values and 
their variation during first-line chemotherapy are summarized on Table 2. 
Stage of the primary, baseline haemoglobin levels >12 g/dl, performance status, and marker 
variation as ordinal variable (groups) confirmed their independent role on TTP. Markers as 
continuous variables, age, grading, and the number of metastatic sites failed to enter the model. 
Variables that demonstrated an independent impact on OS were: number of metastatic sites, baseline 
haemoglobin levels >12 g/dl, Performance status, baseline CA 19-9 values >37 U/ml, clinical 
response to first-line chemotherapy, CEA variation as ordinal variable (groups), and liver or lung 
surgery. Marker as continuous variable, age, and grading failed to demonstrate a prognostic role. 
When marker values were analyzed as time-dependent covariates, CEA and CA 19-9 confirmed 
their independent impact on TTP and OS. 
 
DISCUSSION 
In our study we retrospectively collected data from patients prospectively followed, demonstrating 
that serum values of CEA and CA 19-9 may give prognostic indications independently from other 
well established prognostic factors. Thus, they can be considered as easy-to-obtain, low-cost, 
dynamic clinical tools that may help clinicians to discriminate patients with aggressive tumors. 
Several new biomolecular markers have been proposed: EGFR gene copy number, NRAS, PIK3CA 
mutations, loss of PTEN expression, the presence of Insulin-like growth factor 2 messenger RNA 
binding protein 3 in cancer cells
11-14
 The determination of these factors is costly and some of them 
are experimental and then reserved to specialized centers. Moreover, all these markers are not time-
dependent, and thus they could not reflect a change in tumor biology over time. 
The findings of our study confirmed the recommendation of the guidelines as a good correlation 
between marker change and response to therapy have been documented both for CEA and CA 19-9 
(Figure 1). In addition, we showed that patients with higher values of the markers at the time of first 
metastasis appearance had a shorter survival (Figure 2), as elsewhere described in a selected and 
limited subgroup of patients
15
. We observed patients with discordancy between marker variation 
and response to therapy (marker increase in case of response and marker decrease in case of tumor 
progression) and patients with marker values always beneath the upper normality threshold for the 
entire observation period (see Figure 1). Patients with marker increase during first-line treatment 
were those who had a shorter progression-free and overall survival independently from tumor 
response. When considering only responding patients, in fact, those who reported a CEA or CA 19-
9 increase were those with a shorter PFS and OS. On the other hand, within progressing patients, 
those with marker stabilization or decrease were those with a better PFS and OS (data not shown). 
Moreover, patients with CEA or CA 19-9 values always negative had the longest PFS and OS 
(Figure 3 and 4). These groups have never been described before as patients with marker levels 
always beneath the upper normality threshold have always been excluded as false negative. These 
patients had the longest PFS and OS. A possible explanation for this observation may be the relative 
lower biological aggression of tumor cells which may lead to a lower marker production and a 
slower tumor growth. These data were also confirmed by multivariate analyses in which marker 
values together with stage of the primitive, PS and haemoglobin levels at the time of chemotherapy 
onset were identified as independent prognostic factors. Curiously, both marker kinetics expressed 
as ordinal variables (groups) and not their basal values were independent factors for TTP, reflecting 
the predictive role of these markers in indicating those tumors that were responding to 
chemotherapy. As far as OS is concerned, only CEA and not CA 19-9 kinetic entered the statistical 
model. This could be explained by the low CA 19-9 sensitivity. In fact, only basal CA 19-9 levels 
above the upper limit of normality resulted to be a prognostic factors, probably indicating that those 
patients had a more aggressive and/or a bulky disease at diagnosis. We further analysed data 
according to the model proposed by Boek and coll. In their statistical model, CEA and CA 19-9 
values were entered as time-varying covariates and thus analysing them as continuous variables and 
not as categorized variables, which is a widely used but criticizable approach
16
. We performed this 
more accurate statistical analyses in order to confirm the results in terms of prognostic role of CEA 
and CA 19-9 as categorization of marker variation during time permits an easier application in the 
practical daily routine. To summarize, CEA and CA 19-9 determinations demonstrated to provide 
basal prognostic information contributing with the above mentioned biochemical markers in helping 
clinicians to discriminate aggressive tumors. Differently from those markers, CEA and CA 19-9 
showed to be time-dependent indicators, probably reflecting not only tumor load, but also biological 
variations of cancer cells. 
Our findings computed from a large database drawn from two different institutions are in complete 
accordance to what reported by Strimpakos and coll. in an analysis from a single institution which 
focused primarily to the prognostic role of CEA flare and its kinetic in the same patient setting
17
. 
Authors affirmed that it might be possible that higher serum CEA levels promote disease 
progression and metastasis rather than simply reflect a tumour burden increase. We agree with this 
fascinating hypothesis. However, in our study we observed the same independent prognostic role 
for CA 19-9, a glycoprotein expressed in several neoplastic disease especially gastrointestinal
18,19
, 
and in inflammatory processes such as Hashimoto thyroiditis or viral hepatitis
20,21
. To our 
knowledge, CA 19-9 has never been associated to cell adhesion and/or tumor growth and 
metastatization. Thus, as reported above, we may hypothesize that beside other possible biological 
properties of the markers, CEA or CA 19-9 levels might simply reflect either the tumor burden and 
the metabolic activity of cancer cells, as we already shown for CA 15-3 in advanced breast cancer 
patients
22
.  
We did not find any difference in the prognostic or predictive information of a marker rather than 
the other. CA 19-9 sensitivity at baseline was lower than CEA and a higher number of patients had 
CA 19-9 values always beneath the upper limit threshold. The combination of the two markers 
increased sensitivity from 63,8% to 73,6%. We believe that this 5,8% increase do not worth the 
costs of dosing the two markers in this patient setting, confirming guideline recommendations. 
Thus, our data prompt us to recommend to follow patients with serial dosages of CEA and not of 
CA 19-9. Evaluation of a possible role of basal CA 19-9 dosage in all patients and CA 19-9 serial 
determinations in those few patients in whom baseline CEA is negative and CA19-9 is positive 
could be proposed. 
The main limitations of this investigation arise from its retrospective nature. However, data were 
extracted from clinical database of two institution in which patients were followed prospectively. 
Moreover, in our study we did not included only patients enrolled in experimental clinical trials 
with strict inclusion and exclusion criteria, better reflecting the daily routine. In fact, response rate 
to chemotherapy resulted to be 37.2%, lower than those normally reported for phase II or III studies 
which included selected patients. Thus, our finding could be generalized and applied even outside 
experimental trials. 
In conclusion, baseline and serial evaluations of CEA and CA 19-9 levels in patients with advanced 
colorectal cancer submitted to first-line chemotherapy permitted to obtain prognostic information 
independently from known prognostic factors. CA 19-9 did not add any supplementary information 
and then its dosage is not recommended. A possible role of basal CA 19-9 in all patients and its 
serial determination in those patients with CEA levels below the upper normality limit at baseline 
could worth further evaluation. 
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Figure 1. Correlation between marker variation (Groups) and response to first-line chemotherapy 
(columns). Numbers in the boxes are the percentages of each Group in the respective response 
group (column). 
 
Figure 2. Overall Survival for patients stratified according to marker levels. Differences in OS 
between higher and lower baseline CEA or Ca 19-9 were both statistically significant (p<0.0001) 
 
Figure 3. Overall survival of patients stratified according to CEA variation during first-line 
chemotherapy. Groups were defined as G0 (always negative); G1 (decrease); G2 (stable); and G3 
(increase). 
 
Figure 4. Overall survival of patients stratified according to CA 19-9 variation during first-line 
chemotherapy. Groups were defined as G0 (always negative); G1 (decrease); G2 (stable); and G3 
(increase). 
 
CONSORT Diagram of the Study. 
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Table 1 
 # Patients (%) 
No. of patients 892 
Center 1 644 (72.2) 
Center 2 248 (27.8) 
  
Gender  
Male 549 (61.5) 
Female 343 (38.5) 
  
Age  
Median (range) years 64 (28.9-87.4) 
  
Stage of primary  
A 5 (0.5) 
B 112 (12.6) 
C 240 (26.9) 
D 535 (60.0) 
  
Grading  
1 23 (3.2) 
2 493 (68.4) 
3 205 (28.4) 
Unknown 171 (-) 
  
Disease free interval  
Median (range) months 0.5 (0-218) 
  
Site of recurrence  
Liver 620 (69.5) 
Lung 263 (29.5) 
Other 308 (34.5) 
  
Number of sites of recurrence  
1 640 (71.7) 
2 205 (23.0) 
>2 47 (5.3) 
  
Performance Status  
0-1 721 (92.0) 
2-4 63 (8.0) 
Unknown 105 (-) 
  
First-line chemotherapy  
Oxaliplatin-containing 587 (65.8) 
Irinotecan-containing 75 (8.4) 
Triplet 2 (0.2) 
5FU-based 228 (25.6) 
With Bevacizumab 42 
With anti-EGFR (experimental) 12 
  
Median CEA values (range) ng/ml  
Baseline 15.6 (0.1-32,380) 
3 months 8.5 (0.4-50,000) 
6 months 8 (0.1-68,076) 
  
Median Ca 19-9 values (range) U/ml  
Baseline 29 (0.1-56,000) 
3 months 19.9 (0.1-42,817) 
6 months 20 (0.1-63,630) 
  
 
Table 2. Multivariate Cox analyses on the impact of baseline CEA and Ca 19-9 values and their 
variation during first-line chemotherapy on TTP and OS. 
 
Variable HR (95% CI) p 
 
TTP   
Stage of the primitive* 1.22 (1.16-1.28) <0.001 
Hemoglobin levels > 12 g/dl 0.74 (0.65-0.83) <0.001 
Performance Status (0-4) 1.29 (1.23-1.35) <0.0001 
CEA Group (0-3)§ 1.22 (0.18-1.26) <0.0001 
Ca 19-9 Group (0-3)§ 1.22 (0.18-1.26) <0.0001 
   
OS   
Number of metastatic sites 1.19 (1.13-1.25) 0.005 
Response to chemotherapy (0-2)^ 0.59 (0.52-0.63) <0.0001 
Hemoglobin levels > 12 g/dl 0.76 (0.66-0.86) 0.004 
Performance Status (0-4) 1.34 (1.27-1.41) <0.0001 
Liver surgery (1 yes; 0 no) 0.56 (0.42-0.70) <0.0001 
Lung surgery (1 yes; 0 no) 0.22 (0-0.49) <0.0001 
CEA Group (0-3)§ 1.18 (1.13-1.23) <0.001 
Baseline Ca 19-9 >37 U/ml 1.79 (1.69-1.89) <0.0001 
   
   
Marker as time-dependent covariate 
TTP   
CEA 1.02 (1.01-1.03) 0.05 
Ca 19-9 1.03 (1.02-1.04) 0.007 
Hemoglobin levels > 12 g/dl 0.75 (0.62-0.88) 0.03 
Performance Status (0-4) 1.22 (1.13-1.31) 0.03 
   
OS   
CEA 1.08 (1.06-1.10) <0.0001 
Ca 19-9 1.03 (1.00-1.06) 0.05 
Number of metastatic sites 1.15 (1.09-1.21) 0.01 
Hemoglobin levels > 12 g/dl 0.74 (0.66-0.82) <0.001 
Performance Status (0-4) 1.22 (1.16-1.28) 0.001 
Response to chemotherapy (0-2)^ 0.57 (0.51-0.63) <0.0001 
Liver surgery (1 yes; 0 no) 0.54 (0.42 – 0.66) <0.0001 
Lung surgery (1 yes; 0 no) 0.23 (0.0-0.47) <0.0001 
   
* stage A=0; B=1; C=2; D=3 
§ categorized as per study design: G0=0; G1=1; G2=2; G3=3 
^ progression=0; disease stabilization=1; response=2 
 
 
